The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to determine whether a study medication (d-cycloserine) improves the ability of older adults to perform on tests of neuropsychological functioning. Tests of neuropsychological functioning assess attention, memory, and executive functioning skills (for example, problem-solving, planning and organizing skills). It was hypothesized that participants who received study medication would perform better on neuropsychological tests than would participants who received the sugar pill.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cognitive Effects of Citicoline on Attention in Healthy Mean and Women

NCT04967157

Healthy

COMPLETED NA

Cognitive Effects of Citicoline in Men and Women With Age-Associated Memory Impairment

NCT03369925

Healthy

COMPLETED NA

Cognizin Citicoline Dosing in a Healthy Adolescent Male Population

NCT01582113

Neurocognitive Improvement

COMPLETED EARLY_PHASE1

Improving Sleep and Cognition in Alzheimer's Disease

NCT05200208

Alzheimer Disease

COMPLETED NA

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

NCT04430517

Mild Cognitive Impairment Mild Alzheimer Disease

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Accumulating data support the augmenting effects of d-cycloserine (DCS) when combined with exposure-based treatment for anxiety disorders. Additional research is needed to determine whether DCS facilitates other forms of cognitive processing (e.g., attention, memory, executive functioning) that are involved in cognitive behavioral therapies which do not rely on extinction as a mechanism of action. This question is particularly important among older adults who have experienced normal age-related declines in cognitive functioning, which may interfere with their ability to benefit from cognitive-behavioral therapies. The aim of the current study was to determine the cognitive enhancing effects of DCS on neuropsychological test performance among healthy older adults. It was hypothesized that participants who received d-cycloserine would demonstrate superior performance on neuropsychological tests than would participants who received placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Treatment Placebo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Medication

250 mg d-cycloserine

Group Type EXPERIMENTAL

d-cycloserine

Intervention Type DRUG

single oral administration of 250 mg d-cycloserine

Sugar Pill

Group Type PLACEBO_COMPARATOR

Sugar Pill

Intervention Type DRUG

Single oral administration 250 mg Sugar Pill

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

d-cycloserine

single oral administration of 250 mg d-cycloserine

Intervention Type DRUG

Sugar Pill

Single oral administration 250 mg Sugar Pill

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Seromycin Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 60 or older
* native English speaker

Exclusion Criteria

* diagnosis of current psychiatric disorder
* substance abuse past 3 months
* cognitive impairment
* neurological disorder
* poor health or unstable medical condition
* positive toxicology screen
* current use of isoniazid
* current use of trecator
* severe renal insufficiency

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes